Сталево is generally used for adult patients with idiopathic Parkinson's disease. Its primary therapeutic role is in patients who are already receiving standard levodopa/carbidopa treatment but are experiencing motor fluctuations. This application includes patients whose symptoms are not stable on standard levodopa/carbidopa combinations. The medication is applied in clinical settings when supportive symptom management is appropriate to address these periods of fluctuating movement control.

Core Indications and Symptom Relief

The medication is applied across conditions characterized by periods of heightened symptoms. It is relevant for managing the symptomatic burden associated with end-of-dose motor fluctuations, which involve the predictable, cyclical return of symptoms such as slowness of movement, rigidity, and difficulty performing daily activities. It is relevant for supporting symptomatic relief that may assist with maintaining functional stability and contributes to easing the overall symptom load during symptomatic periods.

“This medicine is considered relevant for supporting the patient’s functional ‘on-time’, which may assist with making daily living more predictable.”

Quick Fact: Supportive Management for Motor Fluctuations

The medication is primarily used to help manage symptoms that interfere with daily comfort during periods of reduced therapeutic benefit from levodopa.

Who can and cannot use Сталево?

This medicine is approved for use only in adult patients (18 years and older) with idiopathic Parkinson's disease experiencing end-of-dose motor fluctuations. Its use is not recommended in the pediatric population as safety and efficacy have not been established.

Absolute Contraindications (Must Not Use)

Official regulatory labeling dictates that Сталево is contraindicated in patients with the following conditions:

• Severe Hepatic Impairment or severe liver disease.
• Narrow-Angle Glaucoma.
• Pheochromocytoma (adrenal gland tumor).
• History of Melanoma or undiagnosed, suspicious skin lesions.
• History of Neuroleptic Malignant Syndrome (NMS) or non-traumatic rhabdomyolysis.
• Concurrent use of non-selective MAO inhibitors.
• Known hypersensitivity to any component of the tablet.

Conditional Use and Special Populations ️

Caution is advised for use in patients with severe renal impairment or mild-to-moderate hepatic impairment, where monitoring may be required. For pregnancy, use is not recommended unless clearly necessary, and patients must not breastfeed while taking this medicine. No dose adjustment is generally required for elderly patients.

Interactions with other medicines and products

Stalevo is a combination product (levodopa, carbidopa, and entacapone), and its interaction profile is a reflection of all three components. It is essential to inform a healthcare provider of all other medications, supplements, and dietary habits.

Combinations to Avoid

• Non-selective Monoamine Oxidase (MAO) Inhibitors: Co-administration is contraindicated due to the risk of a hypertensive crisis (a sudden, dangerous rise in blood pressure). Therapy with these inhibitors must be stopped at least two weeks before starting Stalevo.
• Sympathomimetic Amines: These agents may be potentiated (made stronger) by levodopa, and their use is contraindicated if sympathomimetic agents are also contraindicated for the patient.

Interactions Requiring Caution or Monitoring

How Сталево Works

The mechanism of Сталево utilizes a triple-combination approach to increase the fraction of Levodopa available for conversion into the neurotransmitter Dopamine, thereby modulating output of the basal ganglia motor circuit.

️ Dual Inhibition Stabilizes Levodopa Availability

This domain focuses on the complementary roles of Carbidopa and Entacapone, which function outside the central nervous system. By simultaneously acting as inhibitors of the two primary metabolic enzymes, Aromatic L-Amino Acid Decarboxylase (AADC) and Catechol-O-Methyltransferase (COMT), they limit the peripheral catabolism of the Levodopa precursor. This dual protection prolongs the half-life and stabilizes the plasma concentration of Levodopa, which increases the likelihood of a sustained supply being available for transport into the central nervous system.

Central Precursor Conversion and Dopamine Agonism

Once Levodopa is transported across the Blood-Brain Barrier (via the LNAAT transporter), it enters the striatum where it is converted into the neurotransmitter Dopamine by the resident AADC enzyme. This newly synthesized Dopamine then functions as an agonist on postsynaptic Dopamine Receptors (D1 and D2), which activates the nigrostriatal pathway. The resulting continuous receptor stimulation modulates the output of the basal ganglia motor circuit.

Сталево is administered exclusively via the oral route as a fixed-dose, film-coated tablet. The method of use involves swallowing each tablet whole without crushing, splitting, or chewing, which is necessary for the controlled delivery of the combination components. The medicine is designed for long-term treatment and is typically taken in divided doses throughout the day.

The regimen is individualized, established by substituting the combination tablet for the total amount of levodopa, carbidopa, and entacapone previously received separately. Subsequent adjustments are made by altering the strength of the tablet or by modifying the frequency of administration to optimize therapeutic benefit. There is a maximum recommended daily dose of the entacapone component, which generally does not exceed 1600 mg, translating to a limit on the total number of tablets taken per day.

Contextual usage notes indicate that the medicine may be taken with or without food. However, absorption of the levodopa component may be reduced or delayed when the tablet is taken concurrently with high-protein meals. Regarding special populations, use involves caution in patients with mild to moderate hepatic impairment, where dose reduction may be needed. Furthermore, to avoid interference with absorption, a separation of at least two to three hours is maintained between taking the medicine and any iron supplements. Safety and efficacy in the pediatric population have not been established.

Research Evidence / Overview of Studies for Сталево

Evidence for Patients Experiencing Motor Fluctuations

The primary evidence for Сталево was evaluated in adult patients with Parkinson's disease who were already experiencing motor fluctuations—specifically, the predictable return of movement symptoms, often called "wearing off," between doses of standard levodopa/carbidopa.

The core research consists mainly of short-term, randomized controlled trials (RCTs). These studies were used to explore short-term symptom changes, comparing the triple combination (or its components) with levodopa/carbidopa alone, or with an inactive substance (placebo). Researchers primarily focused on outcomes capturing phases of heightened symptom activity, measuring the patients' total time spent in the "ON" state (when movement is well-controlled) and the total time spent in the "OFF" time (when symptoms return).

Studies monitored the duration and stability of levodopa's presence in the bloodstream. This research explored how symptoms change over time and how they are measured using patient diaries.

Research on Functional Measures and Quality of Life

In addition to tracking "ON" and "OFF" time, research also examined outcomes related to daily functioning and activity level. These studies applied in studies examining patient-reported experiences. To do this, researchers used standardized measurement tools, such as the Unified Parkinson's Disease Rating Scale (UPDRS), to track changes in a patient's motor ability and their ability to perform daily activities.

Studies also explored patient-reported outcomes describing perceived discomfort and the general impact of the condition. Questionnaires were applied in studies examining patient-reported experiences to assess overall Quality of Life (QoL). This research provides context but not individual predictions, helping to contextualize how patients reported their experience during the study period.

What is Still Uncertain About the Research

It is important to understand that the research highlights what is known — and what is still uncertain. Several research limitations are acknowledged:

• Limited Long-Term Data: The primary evidence for measuring changes in daily symptom control is based on trials where follow-up durations were limited (under one year). Extended follow-up primarily comes from observational settings, and these do not provide the same degree of certainty as randomized, double-blind trials.
• Early Disease Utility: Research exploring the use of the combination at the initiation of treatment does not currently indicate whether starting with the triple regimen offers an advantage over starting with dual therapy alone for delaying motor complications.

Key Studies & References Levodopa/Carbidopa/Entacapone Combination Therapy - StatPearls - NCBI Bookshelf

Common questions about Сталево (FAQ)

Q: What is Сталево (Stalevo) and what is it approved for?

A: Сталево is a combination prescription medicine containing three active ingredients: carbidopa, levodopa, and entacapone. It is approved for the treatment of Parkinson's disease in adults who are already taking carbidopa/levodopa and are experiencing "wearing-off" periods toward the end of their dosing intervals. This wearing-off is when the effects of the standard medication lessen and symptoms of Parkinson's disease return or worsen.

Q: What is the main purpose of combining these ingredients?

A: The combination aims to help maintain the amount of levodopa available to the brain for a longer duration compared to levodopa/carbidopa alone. Levodopa is converted into dopamine in the brain, which is thought to be helpful in managing the motor symptoms of Parkinson's disease. The other two components, carbidopa and entacapone, help prevent the early breakdown of levodopa outside of the brain.

Q: What common side effects are associated with this medication?

A: Common side effects reported in clinical studies include dyskinesia (uncontrolled, involuntary movements), nausea, diarrhea, and harmless reddish-brown discoloration of the urine. Other effects may include feeling light-headed or dizzy, or sometimes falling asleep suddenly without warning. It is important to discuss all potential side effects and concerns with a healthcare provider.

Q: What serious warnings or precautions are associated with Сталево?

A: Serious but less common warnings include the possibility of sudden sleep onset during daily activities, which can occur without warning; orthostatic hypotension (a drop in blood pressure when standing, which may lead to fainting); and the development of or worsening of compulsive behaviors (known as impulse control disorders). Patients should also be monitored for signs of depression, hallucinations, and unusual changes in mood or behavior.

Q: Can I stop taking Сталево if I feel better?

A: Patients should not stop taking this medication suddenly unless directed by a healthcare provider. Abruptly stopping treatment may lead to severe changes in Parkinson's symptoms or cause serious side effects similar to a condition called Neuroleptic Malignant Syndrome (NMS), which requires urgent medical attention. All changes to treatment must be made under the guidance of a physician.

How to Store and Dispose of Stalevo (Carbidopa, Levodopa, and Entacapone)

Official regulations require Stalevo film-coated tablets to be stored under specific conditions to maintain product integrity and safety.

Storage Requirements

Disposal Requirements

Stalevo must not be thrown away via household waste or wastewater. Unused or expired medication should be taken to a pharmacist or returned to an authorized drug collection program for disposal according to local environmental regulations.